Scleroderma of the LHA-Ⅱ type gene and the relationship between autoantibodies and clinical research.docVIP

 PAGE \* MERGEFORMAT 15 Scleroderma of the LHA-Ⅱ type gene and the relationship between autoantibodies and clinical research Abstract: To explore the causes of scleroderma, clinical and prognosis, and many scholars studied the scleroderma patients with LHA-Ⅱ type genes, autoantibodies and clinical relevance. The appearance of antibodies were found in each of its own represents a more specific clinical sub-class, its clinical manifestations vary, the production of autoantibodies mainly LHA-DQ, DR genes are associated. Therefore, the detection of autoantibodies in patients with scleroderma to study with LHA-Ⅱ type genes relevant and contribute to understand the causes of scleroderma, clinical and prognosis. Scleroderma is a restricted or diffuse skin and internal organs, connective tissue fibrosis or sclerosis, the last occurrence of the disease characterized by atrophy. According to the scope of involvement, course and prognosis, is divided into two categories of limited scleroderma and systemic scleroderma. Recent studies have shown that each type of scleroderma autoantibodies are related to certain clinical manifestations related to the production of certain autoantibodies with the LHA-Ⅱ gene-related classes are now on the 12 kinds of major scleroderma autoantibodies are summarized below. 1, anti-nuclear antibody (A) Anti-centromere antibody (ACA): ACA of systemic scleroderma (SSc) specificity of the strongest [1,2], in SSc positive rate was 16% -21%, and gender (female), calcinosis, telangiectasia, biliary cirrhosis and limitations of the skin SSc (lcSSc) is associated; and finger (toe) end of ischemia, arthritis, or pulmonary fibrosis significant negative correlation. ACA-positive prognosis good, the 10-year cumulative survival rate was 93%. Another study found that [3], ACA disease in scleroderma spectrum of disease, the positive rate was 30%. Significantly higher than in other connective tissue disease (3%). Detection of ACA for scleroderma sp